INTERNATIONAL JOURNAL OF HEALTH RESEARCH AND DEVELOPMENT (IJHRD)

OSTEOPOROSIS: REVIEW OF TREATMENT MODALITIES

E-ISSN: 7883-6773

P-ISSN: 3457-2861

DOI: https://iigdpublishers.com/article/98

Proficient treatments are accessible for the management of osteoporotic diseases. Anti- resorptive remedies, comprising bisphosphonates and denosumab, increment bone mineral density (BMD) and diminish the hazard of breaks by 20–70%. Bonemineralisation or bimodal-efficacy of medication invigorate bone
arrangement and increment BMD more than the antiresorptive treatments. A couple of investigations have illustrated that these medicines are preferred over anti-resorptive in avoiding breaks in patients with serious osteoporosis. Bone-enhancing or bimodal-action medicines ought to be taken after by anti-resorptive remedies to keep up the break chance diminishment. The BMD picks up realised with bone-enhancing and bimodal- combat medicines are more prominent
in medication-free patients compared to patients previously exposed to anti-resorptive medicines. Nonetheless, the anti-fracture efficacy seems to be protected. Treatment disappointment will frequently lead to a reversal of medication from orally to systemically taken antiresorptive medications or from antiresorptive to bone-forming. Osteoporosis could be an incessant condition and hence needs prolonged therapy to arrange with an individualisation approach of therapy.

Keyword(s) Calcium, Resorption, Bone, Osteoporosis, Osteogenesis.
About the Journal VOLUME 5, ISSUE 2 | December 2022
Quality GOOD

Eman Abdullah & Marwan M. Merkhan

B. Abrahamsen, P. Eiken, D. (2016). Prieto-Alhambra, & R. Eastell, Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: Nationwide cohort and nested case-control study,‖ BMJ, vol. 353, , doi: 10.1136/bmj.i3365.


J. D. Adachi et al., (2001). Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo- controlled extension trial,‖ Arthritis Rheum., vol. 44, no. 1, pp. 202–211, , doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W.


S. P. H. Alexander et al., (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors,‖ Br. J. Pharmacol., vol. 176, no. S1, pp. S21–S141, doi: 10.1111/bph.14748.


E. B. Andrews et al., (2012). The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years,‖ J. Bone Miner. Res., vol. 27, no. 12, pp. 2429–2437, , doi: 10.1002/jbmr.1768.


G. J. Atkins and D. M. Findlay, Osteocyte regulation of bone mineral: A little give and take,‖ Osteoporos. Int., vol. 23, no. 8, pp. 2067–2079, 2012, doi: 10.1007/s00198-012- 1915-z.

article